Figure 2.

The interrelationship of 4.1G expression in different subtypes of breast cancer (BC). (A) In ONCOMINE analysis, the level of 4.1G in basal-like BC was significantly higher than in luminal-like subtype of BC. (B–D) In GOBO analysis, basal-like expression was higherin 4.1G BC than in luminal A, luminal B, and human epidermal growth factor receptor-2 (HER2+) subtype of BC. In addition, triple-negative (TN) sensitive expression was higher in 4.1G than in HER2+ and hormone receptor (HR) subtype of BC. (E) Overexpression of 4.1G in estrogen receptor (ER)-negative BC was significantly higher than in ER-positive subtype of BC. (F) The expression of 4.1G was highest in grade l and lowest in grade 3 of BC.